KREF Board Weighs Sale or Merger as Q3 Revenue Falls 42.5%
KREF is trading near its 52-week low of $5.25 (1.9% above the low).
Summary
A board committee is reviewing strategic options including a sale, merger, asset sale or continuing operations, with no decision or timeline set. That review lands alongside a rough Q3: revenue of $14.58 million fell 42.5% year over year and missed the $18.15 million estimate, and the company posted a $6.4 million common-stockholder loss. KREF resolved three watchlist loans, taking a hit on its Boston life-sciences loan after property values dropped, and repaid both outstanding CLOs. Management warned higher rates and lower refinancing proceeds could push some troubled-asset resolutions from year-end into H1 2027, with further reserves possible. Liquidity stood at $853.5 million against $582.5 million of common stockholders' equity, or $10.14 per share, versus a $5.35 stock price near its 52-week low.
At the time of this announcement, KREF was trading at $5.35 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $305.4M. The 52-week trading range was $5.25 to $9.11. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.